



PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete If Known

Application Number	10/737,361-Conf. #6005
Filing Date	December 15, 2003
First Named Inventor	Mark L. NELSON
Art Unit	1625
Examiner Name	C. C. Chang
Attorney Docket Number	PAZ-178CPCN

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CC	A1*	US-3,226,436	12-28-1965	Petisi, J.P., et al.	
	A2*	US-RE26253	08-15-1967	Petisi, J.P., et al.	
	A3*	US-3,338,963	08-29-1967	Petisi, J.P., et al.	
	A4*	US-3,341,585	09-12-1967	Bitha, P., et al.	
	A5*	US-3,345,410	10-03-1967	Winterbottom, Robert, et al.	
	A6*	US-3,373,196	03/1968	Bitha and Hlavka	
	A7*	US-3,518,306	06-30-1970	Martell Jr., M.J. et al.	
	A8*	US-3,579,579	05-18-1971	Hlavka, J.J., et al.	
	A9*	US-3,901,942	08-26-1975	Luigi, B. et al.	
	A10*	US-3,993,694	11-23-1976	Martin et al.	
	A11*	US-4,024,272	05-17-1977	Rogalski et al.	
	A12*	US-5,248,797	09-28-1993	Sum, P-E	
	A13*	US-5,281,628	01-25-1994	Hlavka, J.J., et al.	
	A14*	US-5,284,963	02-08-1994	Sum, P-E, et al.	
	A15*	US-5,326,759	07-05-1994	Hlavka, J.J., et al.	
	A16*	US-5,328,902	07-12-1994	Sum, P-E, et al.	
	A17*	US-5,371,076	12-06-1994	Lee, V.J., et al.	
	A18*	US-5,380,888	01-10-1995	Sum, P-E, et al.	
	A19*	US-5,386,041	01-31-1995	Sum, P-E, et al.	
	A20*	US-5,401,729	03-28-1995	Sum, P-E, et al.	
	A21*	US-5,401,863	03-28-1995	Hlavka, J.J., et al.	
	A22*	US-5,420,272	05-30-1995	Sum, P-E, et al.	
	A23*	US-5,430,162	07-04-1995	Sum, P-E, et al.	
	A24*	US-5,442,059	08-15-1995	Sum, et al.	
	A25*	US-5,457,096	10-10-1995	Sum, et al.	
	A26*	US-5,466,684	11-14-1995	Sum et al.	
	A27*	US-5,494,903	02-27-1996	Hlavka, J.J., et al.	
	A28*	US-5,495,018	02-27-1996	Sum, P-E, et al.	
	A29*	US-5,495,030	02-27-1996	Sum, P-E, et al.	
	A30*	US-5,495,031	02-27-1996	Sum, P-E, et al.	
	A31*	US-5,512,553	04-30-1996	Sum, P-E, et al.	
	A32*	US-5,529,990	06-25-1996	Hlavka, J.J., et al.	
	A33*	US-5,530,117	06-25-1996	Hlavka, J.J., et al.	
	A34*	US-5,567,692	10-22-1996	Sum, P-E, et al.	
	A35*	US-5,639,742	06-17-1997	Lee, V.J., et al.	
	A36*	US-5,675,030	10-07-1997	Krishnam, L., et al.	
	A37*	US-5,834,450	11-10-1998	Su, W.	
	A38*	US-5,886,175	03-23-1999	Sum, P-E, et al.	
	A39*	US-6,642,270-A1	04-18-2002	Nelson et al.	
	A40*	US-6,818,634-B2	08-01-2002	Nelson et al.	
	A41*	US-20020128237-A1	09-12-2002	Nelson et al.	
	A42*	US-6,500,812-B2	12-31-2002	Nelson et al.	
	A43*	US-6,841,546-B2	05-29-2003	Draper et al.	
	A44*	US-6,846,939-B2	07-03-2003	Nelson et al.	
CC	A45*	US-6,617,318-B1	09-09-2003	Nelson, M.L., et al.	

Examiner Signature	/Celia Chang/	Date Considered	02/27/07
-----------------------	---------------	--------------------	----------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/737,361-Conf. #6005	
			Filing Date	December 15, 2003	
			First Named Inventor	Mark L. NELSON	
			Art Unit	1625	
			Examiner Name	C. C. Chang	
Sheet	2	of	3	Attorney Docket Number	PAZ-178CPCN

CC	A46*	US-6,624,168	09-23-2003	Nelson, M.L., et al.	
	A47*	US-6,683,068-B2	01-27-2004	Nelson, M.L., et al.	
	A48*	US-20040063674-A1	04-01-2004	Levy et al.	
	A49*	US-20040092490-A1	05-13-2004	Draper et al.	
	A50*	US-20040138183-A1	07-15-2004	Nelson et al.	
	A51*	US-20040176334-A1	09-09-2004	Nelson et al.	
	A52*	US-20040214800-A1	10-28-2004	Levy et al.	
	A53*	US-20040214801-A1	10-28-2004	Nelson et al.	
	A54*	US-6,818,635-B2	11-16-2004	Nelson, Mark L., et al.	
	A55*	US-20040242548-A1	12-02-2004	Draper et al.	
	A56*	US-6,833,365-A1	12-21-2004	Levy et al.	
	A57*	US-20040266740-A1	12-30-2004	Huss et al.	
	A58*	US-20050020545-A1	01-27-2005	Draper et al.	
	A59*	US-6,849,615-B2	02-01-2005	Nelson et al.	
	A60*	US-20050026876-A1	02-03-2005	Nelson et al.	
	A61*	US-20050038002-A1	02-17-2005	Nelson et al.	
	A62*	US-20050070510-A1	03-31-2005	Draper et al.	
	A63*	US-20050119235-A1	06-02-2005	Nelson et al.	
	A64*	US-20050137174-A1	06-23-2005	Ohemeng et al.	
	A65*	US-20050143352-A1	06-30-2005	Nelson et al.	
	A66*	US-20050143353-A1	06-30-2005	Nelson et al.	
	A67*	US-20050187198-A1	08-25-2005	Nelson et al.	
	A68*	US-20050215532-A1	09-29-2005	Levy et al.	
	A69*	US-20050250744-A1	11-10-2005	Levy et al.	
	A70*	US-20050282787-A1	12-22-2005	Myers et al.	
	A71*	US-20050288262-A1	12-29-2005	Bandarage et al.	
	A72*	US-20060003971-A1	01-05-2006	Nelson	
	A73*	US-7,001,918-B2	02-21-2006	Huss et al.	
	A74*	US-20060084634-A1	04-20-2006	Huss et al.	
	A75*	US-20060089336-A1	04-27-2006	Nelson et al.	
	A76*	US-7,045,507-B2	05-16-2006	Draper et al.	
	A77*	US-7,056,902-B2	06-06-2006	Nelson et al.	
	A78*	US-7,067,681-A1	06-27-2006	Nelson et al.	
	A79*	US-20060148765-A1	07-06-2006	Nelson, Mark	
	A80*	US-20060166945-A1	07-27-2006	Abato, Paul	
	A81*	US-20060166946-A1	07-27-2006	Nelson et al.	
	A82*	US-7,094,806	08-22-2006	Nelson, Mark	
	A83*	US-20060194773-A1	08-31-2006	Levy, Stuart	
	A84*	US-20060205698-A1	09-14-2006	Nelson et al.	
CC	A85*	US-20060229282-A1	10-12-2006	Nelson et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code‡	Number⁴-Kind Code⁵ (if known)			
CC	B1	GB	921252	03-20-1963	Carlo Erba S.p.A.	
CC	B2	GB	1469384	04-06-1977	Societa Farmaceutici Italia Spa	
CC	B3	WO	95/22529-A1	08-24-1995	Pfizer, Inc.	

Examiner Signature	/Celia Chang/	Date Considered	02/27/07
-----------------------	---------------	--------------------	----------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/737,361-Conf. #6005
				Filing Date	December 15, 2003
				First Named Inventor	Mark L. NELSON
				Art Unit	1625
				Examiner Name	C. C. Chang
Sheet	3	of	3	Attorney Docket Number	PAZ-178CPCN

CC	B4	WO-01/74761-A1	10-11-2001	Trustees of Tufts College		
	B5	WO-02/04406-A2	01-17-2002	Trustees of Tufts College, et al.		
	B6	WO-02/04407-A2	01-17-2002	Trustees of Tufts College, et al.		
	B7	WO-02/072031-A2	09-19-2002	Paratek Pharmaceuticals, Inc.		
	B8	WO-02/072532-A1	09-19-2002	Paratek Pharmaceuticals, Inc.		
	B9	WO-03/005971-A2	01-23-2003	Paratek Pharmaceuticals, Inc.		
CC	B10	WO-03/057169	07-17-2003	Paratek Pharmaceuticals, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
CC	C1	Barden, Timothy C. et al, "Glycylcyclines". 3. 9-Aminodoxycyclinecarboxamides," <i>J. Med. Chem.</i> , Vol. 37:3205-3211 (1994)			
	C2	Berge, S.M. et al, "Pharmaceutical Salts," <i>J. Pharm. Sci.</i> , Vol. 66:1-19 (1977)			
	C3	Koza, Darrell J. et al, "Synthesis and Biological Evaluation of 9-Substituted Tetracycline Derivatives," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 12:2163-2165 (2002)			
	C4	Petersen, P.J. et al, "In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9- <i>t</i> -Butylglycylamido Derivative of Minocycline (GAR-936)," <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 43(4):738-744 (1999)			
	C5	Spencer, John L. et al, "6-Deoxytetracyclines. V.1a 7,9-Disubstituted Products," <i>J. Med. Chem.</i> , Vol. 6:405-407 (1963)			
	C6	Sum, Phaik-Eng et al, "Glycylcyclines. 1. A New Generation of Potent Antibacterial Agents through Modification of 9-Aminotetracyclines," <i>J. Med. Chem.</i> , Vol. 37:184-188 (1994)			
	C7	Sum, Phaik-Eng et al, "Synthesis and Structure-Activity Relationship of Novel Glycylcycline Derivatives Leading to the Discovery of GAR-936," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 9:1459-1462 (1999)			
	C8	Tally, F.T. et al, "Glycylcyclines: a new generation of tetracyclines," <i>Journal of Antimicrobial Chemotherapy</i> , Vol. 35:449-452 (1995)			
	C9	International Search Report for Application No. PCT/US3/07229, dated October 8, 2003			
CC	C10	Supplemental European Search Report for Application No. 0371641637 - 2123, dated February 23, 2006			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Celia Chang/	Date Considered	02/27/07
--------------------	---------------	-----------------	----------